$MTNB News Article - Matinas BioPharma Announces P
Post# of 63
(Total Views: 261)
Posted On: 10/21/2022 10:35:52 AM
$MTNB News Article - Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90% https://marketwirenews.com/news-releases/mati...93348.html
(1)
(0)Matinas BioPharma Holdings (MTNB) Stock Research Links
My Twitter: WhyteStocks
Scroll down for more posts ▼